Research on Neurological Prognosis of Patients Undergoing Heart Valve Surgery

Sponsor
Nanjing University of Traditional Chinese Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05539261
Collaborator
School of Life Science and Technology, Xi'an Jiaotong University (Other), Yuncheng First Hospital (Other)
30
1
39.7
0.8

Study Details

Study Description

Brief Summary

The purpose of this study is to clarify the changes of neurocognitive function of patients undergoing cardiac valve disease before and after surgical treatment under cardiopulmonary bypass operation, and to predict the neurological prognosis of such patients through combined imaging technology, so as to improve and avoid the occurrence of postoperative neurological dysfunction in such patients.

Condition or Disease Intervention/Treatment Phase
  • Device: magnetic resonance image
  • Diagnostic Test: Neuropsychological scale

Detailed Description

This study focuses on brain protection in patients with heart disease. The preoperative brain imaging and consciousness and cognition evaluation results, intraoperative brain monitoring indicators, adverse events of neurological function, brain imaging and consciousness and cognition evaluation results during the postoperative and follow-up periods were recorded. At the same time, serum markers related to perioperative neurological function were obtained to explore the relevant factors affecting neurocognitive function during the perioperative period. The research objectives to investigate the perioperative changes of neurocognitive function in patients undergoing heart valve surgery under cardiopulmonary bypass and the related factors affecting the prognosis of neurocognitive function.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Brain Protection and Neurological Prognosis in Patients With Heart Valve Disease Undergoing Cardiopulmonary Bypass Operation
Anticipated Study Start Date :
Sep 10, 2022
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
HVD

Heart Valve Disease

Device: magnetic resonance image
Imaging data were collected in a strong magnetic field

Diagnostic Test: Neuropsychological scale
Multi dimensional neuropsychological test

HC

Healthy controls

Device: magnetic resonance image
Imaging data were collected in a strong magnetic field

Diagnostic Test: Neuropsychological scale
Multi dimensional neuropsychological test

Outcome Measures

Primary Outcome Measures

  1. Change of brain volume before and after operation [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of brain volume (mm3) are evaluated by structural 3DT1 weighted MRI. Freesurfer software is used to get the measured value of the volume.

  2. Change of brain function connectivity before and after operation [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of brain functional connectivity intensity are evaluated by rest stage functional MRI. DPABI software based on MATLAB is used to get the measured the matrix value of functional connectivity.

Secondary Outcome Measures

  1. Change of brain evaluate basic cognition before and after operation [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of basic cognition is evaluated by Mini-mental State Examination. The minimum value is 0 , and the maximum value is 30. The higher scores mean a better outcome.

  2. Change of executive functions before and after operation evaluated by Trail-Making Test Part A [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of executive functions are first evaluated by Trail-Making Test Part A test. The minimum value is 0 , and the maximum value is 30. This test has no clear maximum and minimum values. If the test completion time exceeds 79 seconds, it means the outcome is abnormal. The higher scores mean a worse outcome.

  3. Change of executive functions before and after operation evaluated by Digit Symbol Coding score [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of executive functions are second evaluated by Digit Symbol Coding score. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 56.53 ± 20.17. The higher scores mean a better outcome.

  4. Change of working memory before and after operation evaluated by Forward Digit Span [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of working memory is first evaluated by Forward Digit Span. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 7.75±1.47. The higher scores mean a better outcome.

  5. Change of working memory before and after operation evaluated by Backward Digit Span [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of working memory is second evaluated by Backward Digit Span. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 5.36±1.91. The higher scores mean a better outcome.

  6. Change of language ability before and after operation [before operation; 7-10 Days after operation; 1 month; 6-12months]

    The change of language ability is evaluated by Chinese Version Verbal Fluency Test. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 19.43±4.81. The higher scores mean a better outcome.

  7. Preliminary judge whether delirium occurs after operation [Witnin 96 hours after operation]

    Delirium is preliminary evaluate using confusion assessment method(CAM). The minimum value is 0 , and the maximum value is 4. The higher scores mean a worse outcome.

  8. Fine judge whether delirium occurs after operation [Witnin 96 hours after operation]

    Delirium is fine evaluated using Delirium Rating Scale(DRS-R-98). The minimum value is 0 , and the maximum value is 39. The higher scores mean a worse outcome.

  9. Change of plasma marker concentration before and after operation [before operation; immediately after operation; 1,2,3,4 Days after operation]

    The change of plasma marker concentration is evaluated by neurofilament light chain(NFL) protein extracted from plasma.

  10. Change of serum marker concentration before and after operation [before operation; immediately after operation; 1,2,3,4 Days after operation]

    The change of serum marker concentration is evaluated by inflammatory cytokine.

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Aged 45-80 years old.

  • Accept heart biological valve replacement or heart valvuloplasty.

  • More than 6 years of Education.

  • At baseline, the score of Mini-mental State Examination (MMSE) scale is more than 23 points

Exclusion Criteria:
  • Patients who failed to obtain informed consent.

  • Preoperative diagnosis of stroke, epilepsy, history of craniocerebral surgery, cerebrovascular disease, psychosis and rescue patients with cardiopulmonary resuscitation before operation.

  • Alcoholism, illiteracy and left-handed.

  • There was severe organ hypoperfusion or organ dysfunction before operation, including: preoperative myocardial infarction < 90 days, renal failure or dialysis, severe liver injury, digestive tract ischemia, spinal cord ischemia and iliac artery occlusion.

  • There are contraindications to magnetic resonance examination, such as claustrophobia and metal implants in the body.

  • Pregnant or lactating women.

  • Participating in other clinical studies will affect the main indicators of this study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yuncheng First Hospital Yuncheng Shanxi China

Sponsors and Collaborators

  • Nanjing University of Traditional Chinese Medicine
  • School of Life Science and Technology, Xi'an Jiaotong University
  • Yuncheng First Hospital

Investigators

  • Principal Investigator: Nengrui Guo, Yuncheng First Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Qianyan Liu, Principal Investgator, Nanjing University of Traditional Chinese Medicine
ClinicalTrials.gov Identifier:
NCT05539261
Other Study ID Numbers:
  • 82071993
First Posted:
Sep 14, 2022
Last Update Posted:
Sep 14, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Qianyan Liu, Principal Investgator, Nanjing University of Traditional Chinese Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2022